PMID- 24936104
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140617
LR  - 20211021
IS  - 0011-393X (Print)
IS  - 0011-393X (Linking)
VI  - 65
IP  - 1
DP  - 2004 Jan
TI  - Efficacy and tolerability of olanzapine in patients with schizophrenia in 
      lithuania: A 13-week, multicenter, open-label, nonrandomized study.
PG  - 57-69
LID - 10.1016/S0011-393X(04)90005-7 [doi]
AB  - BACKGROUND: The atypical antipsychotic olanzapine has been approved for the 
      treatment of schizophrenia in Europe since 1996 but has been used primarily as a 
      second-line treatment to the less expensive typical agents. However, similar to 
      other atypical antipsychotic drugs, olanzapine has a lower risk of inducing 
      extrapyramidal symptoms, tardive dyskinesia, neuroleptic malignant syndrome, and 
      sexual dysfunction compared with the typical antipsychotic drugs. OBJECTIVE: The 
      aim of this study was to determine whether patients with schizophrenia who have a 
      poor response to their present antipsychotic therapy would show improvement when 
      switched to olanzapine. METHODS: This 13-week, multicenter, open-label, 
      nonrandomized trial was conducted at 5 centers in Lithuania. Patients were 
      started on oral olanzapine 10-mg tablets once daily, which could be adjusted by 5 
      mg/d in the dosing range of 5 to 20 mg/d. The primary efficacy measure was the 
      total score on the Brief Psychiatric Rating Scale (BPRS), which was extracted 
      from the Positive and Negative Syndrome Scale (PANSS). Efficacy response rate was 
      defined a priori as the percentage of patients achieving >/=40% improvement in the 
      BPRS total score. Secondary assessments included the PANSS total and BPRS and 
      PANSS subscales and scores on the Clinical Global Impression-Severity of Illness 
      (CGI-S), the CGI-Global Improvement (CGI-I), and the Patient Global 
      Impression-Improvement (PGI-I) tests. Tolerability was primarily measured by 
      assessing the incidence of treatment-emergent adverse events (AEs) according to 
      the Udvalg fuer Kliniske Undersogelser (UKU) Side Effect Rating Scale and 
      laboratory analyses. RESULTS: Twenty-four patients (13 men [54.2%]; mean [SD] 
      age, 32.4 [8.1] years) entered the study. Twenty-three (95.8%) of the 24 patients 
      completed the study. The mean (SD) daily dosage of olanzapine was 11.40 (2.18) 
      mg/d. The total mean (SD) BPRS score improved significantly from 37.8 (7.9) to 
      19.5 (13.7) (P < 0.001). The response rate was 58.3% (14/24 patients). The mean 
      positive and negative BPRS scores and the mean total and subscale PANSS scores 
      all improved significantly from baseline (P < 0.001). The mean (SD) CGI-S score 
      improved significantly from 4.8 (0.8) at baseline to 3.5 (1.1) at end point (P < 
      0.001). Twenty-two patients (91.7%) showed improvement on the CGM scale. Similar 
      improvement was found on the PGM scale. Treatment-emergent AEs occurred in 7 
      patients (29.2%). Improvement was found on 31 of the 48 UKU scale items; no 
      change was shown on 15 items; and slight worsening was shown on 2 items. No 
      clinical abnormalities were detected during the study. CONCLUSION: In this study 
      of Lithuanian patients with schizophrenia, significant improvement was shown in 
      all efficacy measures. In addition, olanzapine was well tolerated in these 
      patients.
FAU - Maciulis, Valentinas
AU  - Maciulis V
AD  - Psychiatric Clinic, Vilnius University, Vilnius, Lithuania.
FAU - Bitter, Istvan
AU  - Bitter I
AD  - Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, 
      Hungary.
FAU - Milasiunas, Raimundas
AU  - Milasiunas R
AD  - Vilnius Mental Health Center, Vilnius, Lithuania.
FAU - Dembinskas, Algirdas
AU  - Dembinskas A
AD  - Psychiatric Clinic, Vilnius University, Vilnius, Lithuania.
FAU - Radavicius, Liaudminas
AU  - Radavicius L
AD  - Vilnius Mental Health Center, Vilnius, Lithuania.
FAU - Kaunas, Algirdas
AU  - Kaunas A
AD  - Psychiatric Clinic, Vilnius University, Vilnius, Lithuania.
FAU - Dossenbach, Martin
AU  - Dossenbach M
AD  - Area Medical Center Vienna, Lilly Regional Operations, Vienna, Austria.
FAU - Walker, Daniel
AU  - Walker D
AD  - Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Curr Ther Res Clin Exp
JT  - Current therapeutic research, clinical and experimental
JID - 0372621
PMC - PMC4052957
OTO - NOTNLM
OT  - antipsychotic
OT  - olanzapine
OT  - psychopathology
OT  - schizophrenia
OT  - tolerability
EDAT- 2004/01/01 00:00
MHDA- 2004/01/01 00:01
PMCR- 2004/01/01
CRDT- 2014/06/18 06:00
PHST- 2004/01/07 00:00 [accepted]
PHST- 2014/06/18 06:00 [entrez]
PHST- 2004/01/01 00:00 [pubmed]
PHST- 2004/01/01 00:01 [medline]
PHST- 2004/01/01 00:00 [pmc-release]
AID - S0011-393X(04)90005-7 [pii]
AID - 10.1016/S0011-393X(04)90005-7 [doi]
PST - ppublish
SO  - Curr Ther Res Clin Exp. 2004 Jan;65(1):57-69. doi: 10.1016/S0011-393X(04)90005-7.